MarketPulse

plaque psoriasis

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Alumis' Psoriasis Drug Shows Strong Phase 3 Results, Paving Way for 2026 FDA Filing

Alumis reports positive Phase 3 results for envudeucitinib, achieving 68% PASI 90 skin clearance in plaque psoriasis patients, with FDA filing planned for late 2026.
ALMSquality of lifeTYK2 inhibitor
BenzingaBenzinga··Vandana Singh

J&J and Protagonist Win FDA Approval for Oral Psoriasis Drug, Challenging AbbVie's Market Dominance

FDA approves Icotyde for psoriasis, triggering $50M payment to Protagonist. Market reacts with AbbVie stock falling 5.20% amid competitive pressure.
JNJABBVPTGXFDA approvalplaque psoriasis
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arcutis Reports Strong 2025 Revenue Growth, Raises 2026 Outlook

Arcutis reported 2025 revenue of $372.1M (123% growth) and raised 2026 guidance to $480-495M, driven by strong ZORYVE adoption and positive clinical data.
ARQTQ4 2025 earningsFDA approval